It’s been seven months since the ACR released its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases, and we continue to learn more about navigating COVID-19 in rheumatology patients. Some real-world data has become available on patient outcomes. The FDA has issued an EUA for 3rd doses of an available mRNA vaccine in certain immunocompromised patients. Antibody testing continues to be heavily debated. And monoclonal antibody treatment has received an EUA to be used as a prophylaxis measure in patients at high risk for developing severe COVID-19. Dr. Jeff Curtis, Chair of the ACR COVID-19 Vaccine Guidance Task Force, joins us to discuss these developments, updated task force recommendations, and more.